ACTG A5201(V 20)-REGMIN SMPLFCTN TO ATAZANAVIR/RITONAVIR AFTR VRLGC SUPPRESSION

ACTG A5201(V 20)-REGMIN SMPLFCTN 至阿扎那韦/利托那韦 AFTR VRLGC 抑制

• 批准号: 7719475
• 负责人: Elizabeth Connick
• 金额: $ 0.15万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719475
• 关键词: AIDS clinical trial group; Adverse effects; Atazanavir; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV; HIV Infections; Institution; Medicine; Nucleosides; Pharmaceutical Preparations; Protease Inhibitor; Purpose; Research; Research Personnel; Resources; Reverse Transcriptase Inhibitors; Ritonavir; Source; Time; United States Food and Drug Administration; United States National Institutes of Health; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. People taking medicines to control their HIV infection normally take at least 3 of these medicines at the same time. For example, a combination might be 2 nucleoside reverse transcriptase inhibitors (NRTI's) and a protease inhibitor. There are several small studies that suggest using a protease inhibitor combined with a low amount of ritonavir (Norvir), another protease inhibitor, can control HIV infection without using other HIV drugs. The main purpose of this research study is to see if taking atazanavir (Reyataz), a protease inhibitor, combined with a low amount of ritonavir will control HIV infection without using other HIV drugs. This study will also see if this treatment is safe in treating HIV infection and if there are any side effects when using atazanavir with ritonavir. Atazanavir and ritonavir are approved by the U.S. Food and Drug Administration (FDA) for use with other HIV drugs in the treatment of HIV infection. Atazanavir with ritonavir is not approved for use without other HIV drugs.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 服用药物控制艾滋病毒感染的人通常同时服用至少3种药物。例如，一个组合可能是2个核苷逆转录酶抑制剂(NRTI‘s)和一个蛋白水解酶抑制剂。 有几项小型研究表明，使用一种蛋白酶抑制剂联合少量的利托那韦(Norvir)，另一种酶抑制剂，可以在不使用其他艾滋病毒药物的情况下控制艾滋病毒感染。这项研究的主要目的是看看服用蛋白酶抑制剂阿塔那韦(Reyataz)联合少量利托那韦是否能在不使用其他艾滋病毒药物的情况下控制艾滋病毒感染。这项研究还将观察这种疗法在治疗艾滋病毒感染方面是否安全，以及在阿扎那韦和利托那韦联合使用时是否有任何副作用。 阿特拉那韦和利托那韦已获得美国食品和药物管理局(FDA)的批准，可与其他HIV药物一起用于治疗HIV感染。他扎那韦和利托那韦不被批准在没有其他艾滋病毒药物的情况下使用。